Back to Search Start Over

C-reactive protein orchestrates acute allograft rejection in vascularized composite allotransplantation via selective activation of monocyte subsets.

Authors :
Kiefer J
Zeller J
Schneider L
Thomé J
McFadyen JD
Hoerbrand IA
Lang F
Deiss E
Bogner B
Schaefer AL
Chevalier N
Horner VK
Kreuzaler S
Kneser U
Kauke-Navarro M
Braig D
Woollard KJ
Pomahac B
Peter K
Eisenhardt SU
Source :
Journal of advanced research [J Adv Res] 2024 Jul 09. Date of Electronic Publication: 2024 Jul 09.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Introduction: Despite advancements in transplant immunology and vascularized composite allotransplantation (VCA), the longevity of allografts remains hindered by the challenge of allograft rejection. The acute-phase response, an immune-inflammatory reaction to ischemia/reperfusion that occurs directly after allogeneic transplantation, serves as a catalyst for graft rejection. This immune response is orchestrated by acute-phase reactants through intricate crosstalk with the mononuclear phagocyte system.<br />Objective: C-reactive protein (CRP), a well-known marker of inflammation, possesses pro-inflammatory properties and exacerbates ischemia/reperfusion injury. Thus, we investigated how CRP impacts acute allograft rejection.<br />Methods: Prompted by clinical observations in facial VCAs, we employed a complex hindlimb transplantation model in rats to investigate the direct impact of CRP on transplant rejection.<br />Results: Our findings demonstrate that CRP expedites allograft rejection and diminishes allograft survival by selectively activating non-classical monocytes. Therapeutic stabilization of CRP abrogates this activating effect on monocytes, thereby attenuating acute allograft rejection. Intravital imagining of graft-infiltrating, recipient-derived monocytes during the early phase of acute rejection corroborated their differential regulation by CRP and their pivotal role in driving the initial stages of graft rejection.<br />Conclusion: The differential activation of recipient-derived monocytes by CRP exacerbates the innate immune response and accelerates clinical allograft rejection. Thus, therapeutic targeting of CRP represents a novel and promising strategy for preventing acute allograft rejection and potentially mitigating chronic allograft rejection.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024. Production and hosting by Elsevier B.V.)

Details

Language :
English
ISSN :
2090-1224
Database :
MEDLINE
Journal :
Journal of advanced research
Publication Type :
Academic Journal
Accession number :
38992424
Full Text :
https://doi.org/10.1016/j.jare.2024.07.007